Floatz logo

ose2101

NSCLC (Non-small Cell Lung Cancer)

OSE ImmunotherapeuticsvaccinePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

1205 Active assets in the NSCLC (Non-small Cell Lung Cancer) cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

ose2101 is also rated in:

Locally Advanced CancerDormant
CCC
Indicative ·
53 / 100
View asset →
ovarian cancerDormant
CCC
Indicative ·
53 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →